Hodgkin's disease was once nearly always fatal; now with proper management most patients can look forward to long survival and probable cure. But the new techniques of management are not themselves without the risk of short-and long-term complications, and this is of particular importance in growing children. Today the challenge of treating the child with Hodgkin's disease is to design therapy which minimizes these potential hazards without in any way reducing the chance of cure.
Incidence
Hodgkin's disease is less common in children than in adults. It is exceedingly rare in the very young: of 64 children referred to the Royal Marsden Hospital in the past 20 years, only one was less than 4 years old. The incidence of the disease then gradually rises with increasing age until adulthood (Jenkin et al., 1967; Fraumeni and Li, 1969; Young et al., 1973) . Curiously, there appears to be a higher incidence in boys than girls, particularly in the younger age groups, and this is associated with a high incidence of lymphocyte predominant histology (see below) in boys (Strum and Rappaport, 1970; Schnitzer et al., 1973; Tan et al., 1975; Smith et al., 1977) . This is much more marked than the marginally increased male incidence in adults (McMahon, 1966) and has not been satisfactorily explained.
Clinical presentation
Most children with Hodgkin's disease present with painless lymphadenopathy in the lower cervical region (Evans and Nyan, 1964; Butler, 1969; Tan et al., 1975) , and about half of these also have mediastinal lymph node involvement. High neck, axillary, and inguinal nodes may also be affected at presentation, but disease presenting solely in one of these sites is much less common than in the neck. In our experience clinical splenomegaly at presentation occurs in only 7 % of children, whereas histological Received 5th May 1977 evidence of disease in the spleen has been found in 8 out of 14 children undergoing laparotomy. Extranodal disease at the time of presentation is nowadays rare, though involvement of lungs, liver, bone, and even skin is occasionally seen (Tan et al., 1975) .
Anorexia, malaise, and lassitude have been described in approximately half of children at presentation, frequently in association with weight loss. Fever has been reported in 25-50% of cases, though rarely of the classical recurrent and relapsing Pel-Ebstein pattern (Evans and Nyhan, 1964) . However, in our recent experience the incidence of these complaints is much less common. This probably relates to increased awareness of the possible significance of cervical lymphadenopathy and hence earlier diagnosis. Drenching night sweats are seldom reported as a presenting complaint in children. Pruritus, usually generalized and occasionally severe enough to cause intense scratching, is sometimes reported by adults with Hodgkin's disease, but in children this is very rare.
Differential diagnosis
Clearly in most of the children who present with cervical lymphadenopathy this will be associated with a simple throat or tonsillar infection, but painless, nontender, rubbery nodes not regressing after antibiotic therapy should alert the paediatrician to the possibility of a lymphoma. At 
Diagnosis and histology
Diagnosis of Hodgkin's disease must be made histologically by biopsy of the lymph node or other affected tissue. Adequacy of the biopsy sample (preferably an intact affected node) and of the technique with which it is taken are both of concern to the pathologist. Procedures that distort nodal architecture, such as needle biopsy and frozen sections, may lead to a wrong diagnosis and should be discouraged. The pathologist needs to be experienced in the diagnosis of lymphomas.
Once the diagnosis has been made the histology is subdivided into various grades. The old subdivision by Jackson and Parker (1947) of paragranuloma, granuloma, and sarcoma has now been replaced by that of Lukes and Butler (1966) , in which the tumour is characterized by the presence of ReedSternberg cells, and graded on the basis of cellular infiltrate and the presence or absence of nodularity. Four subdivisions are identified (Table 1) . Table 1 Hodgkin's disease-histological types, 'Rye' classification (Lukes and Butler, 1966) (1) (Peckham, 1973 Bipedal lymphography permits the inguinal, iliac, and para-aortic lymph nodes to be visualized. The contrast medium then passes up the thoracic duct and may opacify nodes in the mediastinum and the root of the neck, usually on the left side. Opacification of mediastinal nodes is uncommon and frequently associated with involvement of these nodes with tumour. Large masses of tumour in the abdomen may not fill with contrast medium at all, but their presence may be inferred from the displacement of the normal lymphatic architecture or ureters as seen on an intravenous pyelogram which should be done 24 hours after the lymphogram and must be regarded as an essential part of the investigation.
Lymphographically-involved nodes show a foamy or reticular pattern and are frequently enlarged. Filling defects may be present, and a less common pattern is for the nodes to look more dense than normal. It is important to take adequate follow-up films when interpreting lymphograms, as this considerably increases the accuracy of interpretation. Affected nodes enlarge if not treated and shrink on treatment, whereas unaffected nodes remain static when no treatment is given. Sometimes unaffected nodes will become smaller with treatment but they do so symmetrically, whereas affected nodes will shrink more than their normal counterparts. Once the oily contrast medium is in the nodes it usually remains there for about 1 year and sometimes longer, so that follow-up abdominal x-rays can be taken without any further discomfort to the child. (Glatstein et al., 1969) . The operation in adults is safe in experienced hands (Gazet, 1973) , and the more accurate staging leads to more appropriate treatment with increased disease-free survival in patients whose disease remains confined to lymph nodes after operation (Peckham et al., 1975) .
In children, however, there appears to be an increased risk of serious postoperative complications compared with adults. Severe and often fatal infections have recently been reported (Rosenberg, 1971; Hays et al., 1972; Jenkin et al., 1975) , and in particular Chilcoate and Baehner (1975) have documented 20 episodes of septicaemia and meningitis in 200 children after diagnostic laparotomy and splenectomy for Hodgkin's disease; 11 of these children died. These tragedies, which occurred at intervals varing between 8 days and 3 years after operation, were not confined merely to the very young, the average age of children affected being 10 years.
It would be easy to argue on the basis of this experience that no child with Hodgkin's disease should undergo this operation. Yet we have recently seen 4 children with intra-abdominal relapse after complete clinical staging but without laparotomy, and conceivably occult disease might have been diagnosed and eradicated in some of these at presentation had they undergone this procedure. Furthermore, it is particularly important to minimize radiation therapy to unaffected normal tissues in growing children (see below) and the increased accuracy of a staging laparotomy permits limited radiation fields to be planned with greater confidence.
At present there seems to be no easy solution to this dilemma. We feel that children of 10 years and under should not undergo the procedure. In children of 11 and over the advantages of laparotomy and splenectomy seem to outweigh the possible risks, and in these children the procedure should be carried out where radiotherapy, which includes possible intra-abdominal sites of disease, is contemplated. In the infections reported by Chilcoate and Baehner (1975) Diplococcus pneumoniae and other penicillinsensitive organisms were frequently isolated, and we strongly support their recommendation that splenectomized children should receive prophylactic penicillin until the age of 15. These recommendations may have to be modified in the light of future experience, and this problem is being closely looked at in centres throughout the world.
Staging. The extent of disease at the time of diagnosis is staged according to the Ann Arbor system (Carbone et al., 1971) . This is shown in Table 3 , and a few points can be added here. The first is that the use of the suffix E is used to denote involvement of an extranodal site, either where the disease is confined to that site or where there has been direct extension from an adjacent affected lymph node. The implication is that this extranodal disease is still localized and can be treated with radiotherapy. As soon as there is widespread extranodal spread which is not treatable with radiotherapy the disease becomes stage IV. The second point concerns 'B' symptoms, defined on the basis that their presence worsens the prognosis. Pruritus, classically associated with Hodgkin's disease, does not on its own worsen the prognosis and therefore is not categorized as a 'B' symptom. Thirdly, clinical staging and pathological staging must be differentiated. The term clinical staging is applied to a patient who has been fully investigated as described above, but without laparotomy. Pathological staging refers to a patient whose investigation has included laparotomy. This allows more accurate comparisons of treatment results to be made between different centres and also allows the influence of laparotomy on the outcome of treatment to be more readily assessed.
Treatment
Radiotherapy. Gilbert (1939) takes credit for showing that Hodgkin's disease was potentially curable with radiotherapy. His success was based on the concept that lymph node areas adjacent to nodes clinically affected with disease are also potentially affected and should therefore also be irradiated. Peters (1950) and later Kaplan (1962) further developed this principle. Kaplan first described the 'mantle' technique in which cervical, axillary, and mediastinal lymph nodes were irradiated in a single field, and the 'inverted Y' technique in which the para-aortic iliac and inguinal nodes are irradiated in a single field. 'Total nodal' radiotherapy, in which both these techniques were sequentially combined in patients with stage III disease, was developed by Kaplan and Rosenberg (1966) . This approach is known as extended field radiotherpy, and its use in adults with stage I to stage IIIA disease has led to 5-year disease-free survivals and probable cures in the large majority of patients. Similar results with extended field radiotherapy have recently been reported in children Jenkin et al., 1975) and an analysis of children treated by us in this way suggests that about two-thirds of them will remain disease free, and therefore probably cured, after 5 years.
In children, however, extended field radiotherapy carries with it the potential hazard, not seen in adults, of bone growth impairment and organ maldevelopment. Retardation of spinal growth is a common complication of complete spinal irradiation in children, albeit in doses considerably higher than those used for Hodgkin's disease (Probert et al., 1974) . Young et al. (1973) (McElwain et al., 1973) , complete remissions can be achieved in up to 80% of adult patients with stage IIIB and stage IV disease, and the majority of these remain disease free 5 years later. Combination chemotherapy in children with advanced disease is as effective as in adults and this is unquestionably the treatment of choice in children with stage IIIB and stage IV disease. Experience with adults has shown that prior treatment with single drugs is not only vastly less effective but greatly prejudices the likelihood of subsequent long-term response to combination chemotherapy. Single agents should never be used as the initial treatment ofadvanced Hodgkin's disease in children.
In our recent experience the complete remission rate and duration of remission after combination chemotherapy are as good as those in children with less advanced disease treated with radiotherapy. This suggests that chemotherapy could be used in children with less advanced disease and there are some theoretical advantages to this. First, it would eliminate the problem of possible long-term irradiation damage. Second, it would obviate the need for a staging laparotomy with splenectomy, since cryptic areas of intra-abdominal disease would be treated anyway. Third, even if relapse were to occur after chemotherapy, radiotherapy might well remain a curative treatment in many instances, and perhaps at a later stage in the child's development when growth problems were less likely.
On the other hand combination chemotherapy has its own disadvantages. Sterility in adult males, at least for a time after treatment, is inevitable (DeVita et al., 1973) ; the extent to which this will present a long-term problem in children is so far unknown. The induction of second tumours after chemotherapy is also a risk which remains to be assessed. Nausea and vomiting are unpleasant side effects of standard MOPP and MVPP chemotherapy and these can place considerable strain on children, parents, and staff during treatment. Recently, we have explored the possibility of substituting chlorambucil for nitrogen mustard in the 4-drug regimen, and our early experience suggests that this combination is as effective as the original, but with a greatly decreased incidence of drug-associated vomiting .
Our current feelings on the use of chemotherapy in early stage Hodgkin's disease in children are that this approach seems sufficiently promising to warrant further study except where disease is clearly localized, and may be of particular value in children of less than 10 years, where laparotomy would not be carried out (see below). (Peckham et al., 1975) , chemotherapy is in this situation given first to achieve good tumour regression before irradiation. In stage IIIA (with a negative spleen) treatment will depend on the age of the child. It is our policy to treat children of 13 or over with total nodal irradiation as in adults.
In younger children we prefer to use chemotherapy in an attempt to minimize damage to the growing spine. In stage IIIA with splenic involvement, and in stage IIIB disease, chemotherapy is the treatment of choice, possibly followed by irradiation to sites of bulky disease. In stage IV, chemotherapy alone is given, as in adults. All splenectomized children receive oral prophylactic penicillin until aged 15.
Complications during treatment. In general complications during treatment are surprisingly rare, considering the intensity of the therapy. Of the possible infectious problems, the first is herpes zoster, which is otherwise uncommon in children. This is usually self-limiting and is treated with analgesics, though we have occasionally seen good responses to topical idoxuridine (Herpid) The second point concerns management of the disease itself. Most of this can be carried out on an outpatient basis, providing there are no geographical contraindications, and the stability ofthe home background can thus be largely maintained for the child. For younger children the most elaborate investigation will be lymphography and this can be done under light anaesthesia if necessary. Fractionated doses of radiotherapy can also be given on an outpatient basis, and it is surprising how co-operative even young children can be in this. Treatment usually lasts only about one and a half minutes per day, with a few more minutes before this spent setting the child in position. In very young or anxious children light sedation may be desirable. Chemotherapy, given in 2-week courses at 2-week intervals can also be administered on an outpatient basis. this is mostly in tablet form with a single weekly intravenous injection of vinblastine. The combination chemotherapy used in Hodgkin's disease does not produce alopecia, which is obviously; a tremendous psychological advantage, and the problem of vomiting is virtually eliminated using combinations with chlorambucil as described above. The only absolute indication for inpatient care is laparotomy with splenectomy. However, it is our recommendation that this be used only in the older child who can more readily understand the reasons for having to come into hospital.
In recent yeats Hodgkin's disease has become a great success story in modern cancer therapy. Many problems remain to be solved, particularly in children, and there is certainly no room for complacency. The most important point is that successful therapy and the chance of cure depend fundamentally on correct management. Inadequate staging or inappropriate therapy can still quite literally mean the difference between life and death.
Conclusions
Hodgkin's disease in childhood is essentially similar to that in adults, although boys outnumber girls before puberty. It is essential that children with this disease are fully investigated, and in older children investigation should probably include diagnostic laparotomy and splenectomy. In younger children splenectomy is best avoided because of the subsequent danger of infection, and this dictates the need for chemotherapy in most patients in order that all potential disease is treated. Modern techniques of radiotherapy and chemotherapy are both capable of curing the majority of children. The choice of treatment should be designed to ensure the best chance of eradication of the disease with minimum damage to the patient, particularly in terms of subsequent growth and development.
Six courses are given with 2 weeks' rest between the end of one course and the beginning of the next one. Prednisone was given in courses 1 and 4 only, but most workers now give prednisone in every course.
MVPP. (McElwain et al., 1973 . Complete remission rate 76 * 6%.) Mustine hydrochloride 6 mg/M2 IV on days 1 and 8. Vinblastine 6 mg/M2 IV on days 1 and 8. Procarbazine 100 mg/M2 orally daily on days 1-14 inclusive. Prednisone 40 mg/M2 orally daily on days 1-14 inclusive. (A total dose of 40 mg is not exceeded.) 6-10 courses are given with one month's rest between the end of one course and the beginning of the next. Chl VPP. . Complete remission rate 75 * 7 %.) Chlorambucil 6 mg/M2 orally daily on days 1-14 inclusive. (A total dose of 10 mg is not exceeded.) Vinblastine 6 mg/M2 IV on days 1 and 8. Procarbazine 100 mg/M2 orally daily on days 1-14 inclusive. Prednisone 40 mg/M2 orally daily on days 1-14 inclusive. (A total dose of 40 mg is not exceeded.)
6-10 courses are given with 2 weeks' rest between the end of one course and the beginning of the next.
MRC/DHSS Phenylketonuria Register
The attention of interested parties is drawn to the fact that the PKU Register, which hitherto has been in Liverpool, is to be moved to London. 
